Paroxetine Hydrochloride has 40 known drug interactions based on U.S. FDA drug labeling data. Of these, 9 are contraindicated combinations that should be avoided entirely. 5 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Isocarboxazid, Linezolid, Methylene Blue. Patients taking Paroxetine Hydrochloride should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 40
- Contraindicated
- 9
- Major
- 5
- Moderate
- 20
Contraindicated (9)
- Paroxetine Hydrochloride + Isocarboxazid— Concomitant use of SSRIs including paroxetine and MAOIs increases the risk of serotonin syndrome.
- Paroxetine Hydrochloride + Linezolid— Concomitant use of SSRIs including paroxetine and MAOIs increases the risk of serotonin syndrome.
- Paroxetine Hydrochloride + Methylene Blue— Concomitant use of SSRIs including paroxetine and MAOIs increases the risk of serotonin syndrome.
- Paroxetine Hydrochloride + Monoamine Oxidase Inhibitors (Maois)— Contraindicated based on CONTRAINDICATIONS and WARNINGS sections.
- Paroxetine Hydrochloride + Phenelzine— Concomitant use of SSRIs including paroxetine and MAOIs increases the risk of serotonin syndrome.
- Paroxetine Hydrochloride + Pimozide— Increased plasma concentrations of pimozide may increase the risk of QTc prolongation and ventricular arrhythmias.
- Paroxetine Hydrochloride + Selegiline— Concomitant use of SSRIs including paroxetine and MAOIs increases the risk of serotonin syndrome.
- Paroxetine Hydrochloride + Thioridazine— Increased plasma concentrations of thioridazine may increase the risk of QTc prolongation and ventricular arrhythmias.
- Paroxetine Hydrochloride + Tranylcypromine— Concomitant use of SSRIs including paroxetine and MAOIs increases the risk of serotonin syndrome.
Major (5)
- Paroxetine Hydrochloride + Acetylsalicylic Acid— Increased bleeding risk when combined with paroxetine due to platelet dysfunction. Inform patients of increased bleeding…
- Paroxetine Hydrochloride + Clopidogrel— Increased bleeding risk when combined with paroxetine. Inform patients of increased bleeding risk.
- Paroxetine Hydrochloride + Heparin— Increased bleeding risk when combined with paroxetine. Inform patients of increased bleeding risk.
- Paroxetine Hydrochloride + Tamoxifen— Paroxetine's CYP2D6 inhibition may decrease tamoxifen efficacy. Consider alternative antidepressant with little or no CY…
- Paroxetine Hydrochloride + Warfarin— Increased plasma concentrations due to protein binding and CYP2D6 inhibition; increased bleeding risk. Monitor INR caref…
Moderate (20)
- Paroxetine Hydrochloride + Amphetamine— Concomitant use of serotonergic drugs with paroxetine increases the risk of serotonin syndrome. Monitor for symptoms.
- Paroxetine Hydrochloride + Atomoxetine— Paroxetine inhibits CYP2D6, increasing exposure of atomoxetine. Dosage reduction may be needed.
- Paroxetine Hydrochloride + Buspirone— Concomitant use of serotonergic drugs with paroxetine increases the risk of serotonin syndrome. Monitor for symptoms.
- Paroxetine Hydrochloride + Cimetidine— Cimetidine inhibits CYP450 enzymes, increasing paroxetine steady-state plasma concentrations by approximately 50%.
- Paroxetine Hydrochloride + Desipramine— Paroxetine inhibits CYP2D6, increasing exposure of desipramine. Dosage reduction may be needed.
- Paroxetine Hydrochloride + Dextromethorphan— Paroxetine inhibits CYP2D6, increasing exposure of dextromethorphan. Dosage reduction may be needed.
- Paroxetine Hydrochloride + Fentanyl— Caution advised due to potential for serotonin syndrome when coadministered with paroxetine.
- Paroxetine Hydrochloride + Flecainide— Paroxetine inhibits CYP2D6, increasing exposure of flecainide. Dosage reduction may be needed.
- Paroxetine Hydrochloride + Lithium— Concomitant use of serotonergic drugs with paroxetine increases the risk of serotonin syndrome. Monitor for symptoms.
- Paroxetine Hydrochloride + Metoprolol— Paroxetine inhibits CYP2D6, increasing exposure of metoprolol. Dosage reduction may be needed.
- Paroxetine Hydrochloride + Nebivolol— Increased exposure of CYP2D6 substrate; decrease dosage if needed.
- Paroxetine Hydrochloride + Perphenazine— Increased exposure of CYP2D6 substrate; decrease dosage if needed.
- Paroxetine Hydrochloride + Propafenone— Paroxetine inhibits CYP2D6, increasing exposure of propafenone. Dosage reduction may be needed.
- Paroxetine Hydrochloride + Risperidone— Increased exposure of CYP2D6 substrate; decrease dosage if needed.
- Paroxetine Hydrochloride + St. John'S Wort— Concomitant use of serotonergic drugs with paroxetine increases the risk of serotonin syndrome. Monitor for symptoms.
- Paroxetine Hydrochloride + Tolterodine— Increased exposure of CYP2D6 substrate; decrease dosage if needed.
- Paroxetine Hydrochloride + Tramadol— Caution advised due to potential for serotonin syndrome when coadministered with paroxetine.
- Paroxetine Hydrochloride + Triptans— Concomitant use of serotonergic drugs with paroxetine increases the risk of serotonin syndrome. Monitor for symptoms.
- Paroxetine Hydrochloride + Tryptophan— Concomitant use of serotonergic drugs with paroxetine increases the risk of serotonin syndrome. Monitor for symptoms.
- Paroxetine Hydrochloride + Venlafaxine— Increased exposure of CYP2D6 substrate; decrease dosage if needed.